Theracryf Plc · LSE:TCF
Theracryf — Evgen Pharma — Corporate Update (2023)
13 slides from Theracryf's corporate update, 2023
Slide 1: Corporate Summary
Corporate Summary AIM: EVG.L NOMAD: Cavendish IR: Instinctif, CAG
Slide 2: Confidential presentation disclaimer
THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA
Slide 3: Evgen - A Clinical Stage Drug Development Company
Evgen - A Clinical Stage Drug Development Company Focus on brain, breast and other cancers SFX-01 has three molecular targets, STAT 3, Nrf2 and SHP2 • Developing a new class of pharmaceuticals - based on highly biologically active “sulforaphane” - applications in multiple therapeutic areas based on
Slide 4: External Validation of Technology
External Conserve Cash Validation of Technology Biotech Imperatives 2023 Generate Generate Pre- Clinical clinical Data Data
Slide 5: Our Pipeline
Our Pipeline & Rhabdomyosarcoma
Slide 6: SFX-01 in HR+ HER2- Breast Cancer
SFX-01 in HR+ HER 2- Breast Cancer Breast cancer - genetically and clinically heterogeneous disease with multiple subtypes. HR+ HER2- subtype is the most common of all the breast cancer subtypes. The total market size in the 8MM for HER2- breast cancer is estimated to expand to $12.22 billion by 2
Slide 7: SFX-01 in Glioblastoma
SFX-01 in Glioblastoma Very poor life expectancy, average time to death after diagnosis 14 months, 5% five-year survival. Current treatments: surgical resection, radiotherapy and chemotherapy, frequent relapses Epidemiologists forecast an increase in the diagnosed incident cases of brain cancer
Slide 8: SFX-01 in Rhabdomyosarcoma cells and rhabdospheres
SFX-01 in Rhabdomyosarcoma cells and rhabdospheres Published at ESMO sarcoma and rare diseases congress. Lugano 20-22 March 2023 DMSO (Vehicle) SFX-01 • SFX-01 reduced rhabdomyosarcoma tumour cell growth 0Gy • SFX-01 produced a reduction in cell growth that was synergistic with radiation 4Gy • SFX-0
Slide 9: Half Year Highlights to 30 September 2023
Half Year Highlights to 30 September 2023 Phase 1/1b Healthy To evaluate PK and PD effects of new SFX-01 formulation. PK Results delivered on Volunteer clinical schedule study PK Data QA review complete, tables and listings finalised Stalicla SA Phase 1/1b study results shared with Stalicla Collabor
Slide 10: Outlook
Outlook • Full data set from Phase 1b SFX-01 healthy volunteer study including gene expression data – RNA Seq • Evgen analysis • Stalicla analysis in autism – related genes • Start of Grant-funded GBM project in Erasmus MC Rotterdam, pre-clinical data 1/10/23 • 2023 - 2024 pre-clinical data flow • C
Slide 11: External Validation of Technology
External Conserve Cash Validation of Technology Biotech Imperatives 2023 Generate Generate Pre- Clinical clinical Data Data
Slide 12: External Validation of Technology
External Validation of Conserve Cash Technology Runway to Q4 Stalicla, 2024 Academic Centres Biotech Imperatives 2023 Generate Pre- Generate clinical Data Clinical Data La Sapienza, Erasmus, Phase 1 PK/PD, Michigan Erasmus GBM
Slide 13: Contact details
AIM: EVG.L NOMAD: Cavendish IR: Instinctif, CAG Evgen Pharma Plc [email protected] www.evgen.com